Puyuan Xing

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Fei Ma, Qiao Li, Shanshan Chen et al. · Journal of Clinical Oncology · 2017 · 228 citations

Metastatic Breast Cancer, Oncology, Biomarker Analysis +12

Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey

Jufang Shi, Le Wang, Ning Wu et al. · Lung Cancer · 2018 · 132 citations

Medical Service Utilization, Oncology, Cancer Epidemiology +10

Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Qiao Li, Xiuwen Guan, Shanshan Chen et al. · Clinical Cancer Research · 2019 · 89 citations

A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy

Jing Huang, Yi Zhou, Hong‐Tu Zhang et al. · Medical Oncology · 2012 · 79 citations

Esophageal Cancer, Medicine, Biweekly Paclitaxel +9

What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China

Puyuan Xing, Yixiang Zhu, Le Wang et al. · Cancer Medicine · 2019 · 75 citations · Full text